default author photo

Alexander Lazar

University of Texas MD Anderson Cancer Center - Department of Translational Molecular Pathology

2130 West Holcombe Boulevard, Suite 910

Houston, TX 77030

United States

SCHOLARLY PAPERS

2

DOWNLOADS

133

TOTAL CITATIONS

1

Scholarly Papers (2)

1.

Interleukin-6 Blockade Abrogates Immunotherapy Toxicity and Promotes Tumor Immunity

Number of pages: 70 Posted: 19 Mar 2021
University of Texas at Houston - Department of Melanoma Medical Oncology, University of Texas at Houston - Department of Melanoma Medical Oncology, University of Texas at Houston - Department of Melanoma Medical Oncology, University of Texas at Houston - Department of Pathology, University of Texas at Houston - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas at Houston - Department of Melanoma Medical Oncology, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Melanoma Medical Oncology, University of Texas at Houston - Department of Melanoma Medical Oncology, University of Texas at Houston - Department of Melanoma Medical Oncology, University of Texas at Houston - Department of General Internal Medicine, University of Texas at Houston - Department of Immunology, University of Texas MD Anderson Cancer Center - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Gastroenterology, Hepatology, and Nutrition, MD Anderson Cancer Center - Department of Gastroenterology, Hepatology and Nutrition, University of Texas at Houston - Pharmacy Clinical Programs, University of Texas at Houston - Pharmacy Clinical Programs, University of Texas at Houston - Department of Melanoma Medical Oncology, University of Texas at Houston - Department of Leukemia, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Melanoma Medical Oncology, University of Texas at Houston - Department of Melanoma Medical Oncology, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Pathology, University of Texas at Houston - Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center - Department of Melanoma Medical Oncology, University of Texas at Houston - Department of Melanoma Medical Oncology, University of Texas at Houston - Department of Melanoma Medical Oncology and University of Texas at Houston - Department of Melanoma Medical Oncology
Downloads 92 (730,864)

Abstract:

Loading...

Immunity, Toxicity, Colitis, Arthritis, Immune checkpoint blockade, Interleukin-6, Melanoma, TC1/TC-17, Th1/Th17, EAE

2.

Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma

Number of pages: 72 Posted: 18 Mar 2020
University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Surgical Oncology, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center - Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, Jackson Laboratory for Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center - Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center - Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, University of Texas at Houston - Department of Genomic Medicine, University of Texas MD Anderson Cancer Center - Department of Molecular and Cellular Oncology and University of Texas MD Anderson Cancer Center - Department of Genomic Medicine
Downloads 41 (1,170,409)
Citation 1

Abstract:

Loading...

Melanoma, KMT2D, Enhancer, Glycolysis, Chromatin, Epigenetics